Clinical trials
catalyst calendar across sponsors →Studies where SLS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 expanded access · 4 with posted results
Held by 5 tracked-famous managers (SUSQUEHANNA INTERNATIONAL GROUP, LLP, JANE STREET GROUP, LLC, RENAISSANCE TECHNOLOGIES LLC, AQR CAPITAL MANAGEMENT LLC, Squarepoint Ops LLC) · FINRA short interest 7.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLNCT04588922Safety and Tolerability: Dose Limiting Toxicities (DLTs)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: SLS009, venetoclax, azacitidine | Hematologic Malignancies | 160 | 2026-12-30 | in 133 d | 2026-07-29 |
| Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2NCT04229979OSRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Biological: Galinpepimut-S, GM-CSF · Drug: Azacitidine, Venetoclax, Decitabine, Cytarabine · Other: Observation, Montanide | Acute Myeloid Leukemia | 127 | Dec 2025 | — | 2025-10-01 |
| Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersNCT03761914results2024-11-19Overall Response Rate (ORR) - Best Overall ResponseNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: galinpepimut-S, pembrolizumab, GM-CSF · Other: Montanide | Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer | 26 | 2022-07-05actual | — | 2024-11-19 |
| WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell TransplantationNCT01827137results2024-09-19WT1 T-cell Immune Response (IR) 12-14 Weeks After First GPS Administration (6 x Administrations)Open-label · Treatment | Phase 1/2 | Completed | Biological: Galinpepimut-S, GM-CSF · Other: Montanide · Drug: lenalidomide, bortezomib | Multiple Myeloma | 20 | 2016-12-07actual | — | 2024-09-19 |
| Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality TherapyNCT01265433results2024-10-091-year Progression-free SurvivalRandomized · Double-masked · TreatmentStudy Protocol, Statistical Analysis Plan, and Informed Consent Form ↗ | Phase 2 | Completed | Biological: Galinpepimut-S + Montanide + GM-CSF, Montanide + GM-CSF | Malignant Pleural Mesothelioma | 41 | 2016-11-30actual | — | 2024-10-09 |
| WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)NCT01266083results2024-11-19Overall SurvivalOpen-label · Treatment | Phase 2 | Completed | Biological: Galinpepimut-S, GM-CSF · Other: Montanide | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | 22 | 2016-09-30actual | — | 2024-11-19 |
| Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDSNCT05593185expanded access | — | Available | Biological: Galinpepimut-S | Acute Myeloid Leukemia, Myelodysplastic Syndromes | — | — | — | 2026-04-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19